Could a custom vaccine slow Alzheimer's? new trial begins
NCT ID NCT05834296
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This study tests a new treatment called ALZN002 for people with mild-to-moderate Alzheimer's disease. It uses a person's own immune cells, trained to target a protein linked to Alzheimer's, to try to slow the disease. The trial involves 30 participants and aims to check if the treatment is safe and tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Excellent Research Group
Doral, Florida, 33186, United States
Conditions
Explore the condition pages connected to this study.